{"disease":{"id":"ovarian","name":"ovarian"},"drugs":{"marketed":[{"drug_id":"pf-07104091-monotherapy-dose-expansion-ovarian","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07104091 monotherapy dose expansion (ovarian)","generic_name":"pf-07104091-monotherapy-dose-expansion-ovarian","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[insert molecular target]","drug_class":"small molecule","quality_score":35,"revenue":"798","mechanism":""},{"drug_id":"rucaparib","indication_name":"Maintenance treatment of BRCA-mutated recurrent ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rubraca","generic_name":"RUCAPARIB","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP-1, PARP-2, PARP-3","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rucaparib inhibits PARP enzymes, causing DNA damage and cancer cell death, especially in cells with BRCA1/2 deficiencies."},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Ovarian Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"chembl-chembl11359","indication_name":"Metastatic Ovarian Tumors - Combination Therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CISPLATIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Platinum-based Drug [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl11359","indication_name":"Metastatic Ovarian Tumors - Refractory to Standard Chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CISPLATIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Platinum-based Drug [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl428647","indication_name":"Advanced ovarian carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PACLITAXEL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Microtubule Inhibitor [EPC]","quality_score":37,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl428647","indication_name":"First-line ovarian carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PACLITAXEL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Microtubule Inhibitor [EPC]","quality_score":37,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"estradiol-valerate","indication_name":"Primary ovarian failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Delestrogen","generic_name":"ESTRADIOL VALERATE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":65,"revenue":null,"mechanism":"Delestrogen works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"clomifene","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Clomid","generic_name":"clomifene","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase","drug_class":"Estrogen Agonist/Antagonist","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"norethisterone","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micronor","generic_name":"norethisterone","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"GnRH receptors","drug_class":"Progestin","quality_score":63,"revenue":null,"mechanism":"ORIAHNN combines elagolix, which suppresses LH and FSH to reduce ovarian sex hormones, with estradiol and norethindrone acetate to mitigate side effects."},{"drug_id":"norethisterone","indication_name":"Primary ovarian failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micronor","generic_name":"norethisterone","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"GnRH receptors","drug_class":"Progestin","quality_score":63,"revenue":null,"mechanism":"ORIAHNN combines elagolix, which suppresses LH and FSH to reduce ovarian sex hormones, with estradiol and norethindrone acetate to mitigate side effects."},{"drug_id":"norethisterone","indication_name":"Vasomotor symptoms associated with ovarian deficiency symptoms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micronor","generic_name":"norethisterone","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"GnRH receptors","drug_class":"Progestin","quality_score":63,"revenue":null,"mechanism":"ORIAHNN combines elagolix, which suppresses LH and FSH to reduce ovarian sex hormones, with estradiol and norethindrone acetate to mitigate side effects."},{"drug_id":"dostinex","indication_name":"Prevention of ovarian hyperstimulation syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dostinex","company_name":"Par Pharmaceutical, Inc.","drug_phase":"phase_1","molecular_target":"D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A","drug_class":"","quality_score":27,"revenue":null,"mechanism":null},{"drug_id":"avutometinib","indication_name":"KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avmapki Fakzynja Co-Pack","generic_name":"AVUTOMETINIB","company_name":"Verastem Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Avmapki Fakzynja Co-Pack works by blocking a protein that helps cancer cells grow."},{"drug_id":"avutometinib","indication_name":"KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avmapki Fakzynja Co-Pack","generic_name":"AVUTOMETINIB","company_name":"Verastem Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Avmapki Fakzynja Co-Pack works by blocking a protein that helps cancer cells grow."},{"drug_id":"cetrorelix","indication_name":"Prevention of premature ovulation during controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cetrotide","generic_name":"CETRORELIX","company_name":"Merck KGaA","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Antagonist","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"estradiol","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"estradiol","indication_name":"Ovarian deficiency symptoms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"estradiol","indication_name":"Primary ovarian failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"clindamycin-phosphate","indication_name":"Anaerobic Tubo-Ovarian Abscess","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cleocin T","generic_name":"CLINDAMYCIN PHOSPHATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Lincosamide Antibacterial","quality_score":51,"revenue":null,"mechanism":"Cleocin T works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death."},{"drug_id":"medroxyprogesterone","indication_name":"Prevention of premature ovulation during controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Provera","generic_name":"medroxyprogesterone","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Progesterone receptor","drug_class":"Progestin","quality_score":null,"revenue":null,"mechanism":"Depo-Provera works by binding to the progesterone receptor in the body, which helps to regulate the menstrual cycle and prevent pregnancy."},{"drug_id":"ganirelix","indication_name":"Prevention of Luteinizing Hormone Surge when undergoing Controlled Ovarian Hyperstimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ganirelix Acetate","generic_name":"GANIRELIX","company_name":"Organon Usa Organon","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"Gonadotropin Releasing Hormone Receptor Antagonist","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"clindamycin","indication_name":"Anaerobic Tubo-Ovarian Abscess","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cleocin","generic_name":"clindamycin","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"50S ribosomal protein L10","drug_class":"Lincosamide antibiotic","quality_score":56,"revenue":null,"mechanism":"Lincosamide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with excellent anaerobic coverage."},{"drug_id":"dydrogesterone","indication_name":"Prevention of premature ovulation during controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gynorest","generic_name":"DYDROGESTERONE","company_name":"Solvay","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"dydrogesterone","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"cisplatin","indication_name":"Ovarian Germ Cell Tumor Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Platinol-Aq","generic_name":"cisplatin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Platinum-based Drug [EPC]","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"metronidazole","indication_name":"Bacteroides Tubo-Ovarian Abscess","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"metronidazole","indication_name":"Clostridium Tubo-Ovarian Abscess","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"metronidazole","indication_name":"Peptococcus Tubo-Ovarian Abscess","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"metronidazole","indication_name":"Peptostreptococcus Tubo-Ovarian Abscess","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"metronidazole","indication_name":"Tubo-ovarian abscess","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"metformin","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucophage","generic_name":"metformin","company_name":"Generic (originally Merck Serono/Lipha)","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Activates AMP-activated protein kinase (AMPK) to reduce hepatic glucose production and improve insulin sensitivity without causing hypoglycemia."},{"drug_id":"metformin","indication_name":"Induction of ovulation in polycystic ovarian syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucophage","generic_name":"metformin","company_name":"Generic (originally Merck Serono/Lipha)","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Activates AMP-activated protein kinase (AMPK) to reduce hepatic glucose production and improve insulin sensitivity without causing hypoglycemia."},{"drug_id":"clomid","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clomid","company_name":"rana alaaeldin aly ibrahim nasr","drug_phase":"phase_1","molecular_target":"3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 6, Adenosine receptor A3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"menest","indication_name":"Primary ovarian failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Menest","generic_name":"Estrogens, Esterified","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Esterified estrogens, sold under the brand names Estratab and Menest, are used for hormone therapy and cancer treatment."},{"drug_id":"levonorgestrel","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jadelle","generic_name":"LEVONORGESTREL","company_name":"Fdn Consumer","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Progestin","quality_score":10,"revenue":null,"mechanism":"Jadelle works by binding to the progesterone receptor, which helps to prevent ovulation and thicken cervical mucus to prevent sperm from reaching the egg."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic ovarian carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"adriacin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"endometrin","indication_name":"Amenorrhea Secondary to Ovarian Dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endometrin","generic_name":"progesterone","company_name":"Ferring","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"Progesterone [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cetrotide","indication_name":"Prevention of premature ovulation during controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cetrotide","company_name":"Wolfson Medical Center","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor, Lutropin-choriogonadotropic hormone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"glucophage","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glucophage","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"glucophage","indication_name":"Induction of ovulation in polycystic ovarian syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glucophage","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ethinylestradiol","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ortho-Novum 10/11-21","generic_name":"Ethinylestradiol","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"estring","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"estring","indication_name":"Ovarian deficiency symptoms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"estring","indication_name":"Primary ovarian failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"femara","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Femara","company_name":"M.D. Anderson Cancer Center","drug_phase":"discontinued","molecular_target":"Cytochrome P450 11B2, mitochondrial, Aromatase, Cytochrome P450 11B1, mitochondrial","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"femara","indication_name":"Induction of ovulation in polycystic ovarian syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Femara","company_name":"M.D. Anderson Cancer Center","drug_phase":"discontinued","molecular_target":"Cytochrome P450 11B2, mitochondrial, Aromatase, Cytochrome P450 11B1, mitochondrial","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"letrozole","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Femara","generic_name":"letrozole","company_name":"Novartis AG","drug_phase":"marketed","molecular_target":"aromatase enzyme","drug_class":"Aromatase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Letrozole reduces estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogens."},{"drug_id":"letrozole","indication_name":"Induction of ovulation in polycystic ovarian syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Femara","generic_name":"letrozole","company_name":"Novartis AG","drug_phase":"marketed","molecular_target":"aromatase enzyme","drug_class":"Aromatase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Letrozole reduces estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogens."},{"drug_id":"estradiol-cypionate","indication_name":"Primary ovarian failure","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depoestradiol","generic_name":"ESTRADIOL CYPIONATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cabergoline","indication_name":"Prevention of ovarian hyperstimulation syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dostinex","generic_name":"CABERGOLINE","company_name":"Pfizer Japan Inc.","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Ergot Derivative [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"drospirenone","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Slynd","generic_name":"DROSPIRENONE","company_name":"Exeltis Usa Inc","drug_phase":"marketed","molecular_target":"Mineralocorticoid receptor","drug_class":"Progestin","quality_score":75,"revenue":null,"mechanism":"Slynd works by binding to the mineralocorticoid receptor, a protein that plays a role in hormone regulation."},{"drug_id":"chorionic-gonadotrophin","indication_name":"Controlled ovarian stimulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Choriogonadotropin","generic_name":"chorionic gonadotrophin","company_name":"Ferring","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bevacizumab-maly","indication_name":"Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"hydroxydaunomycin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cytalux","indication_name":"Imaging ovarian cancer and malignant lesions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cytalux","company_name":"Ann & Robert H Lurie Children's Hospital of Chicago","drug_phase":"marketed","molecular_target":"Folate receptor alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"progesteron","indication_name":"Amenorrhea Secondary to Ovarian Dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Progesteron","company_name":"Minia University","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metronidazol","indication_name":"Bacteroides Tubo-Ovarian Abscess","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metronidazol","indication_name":"Clostridium Tubo-Ovarian Abscess","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metronidazol","indication_name":"Peptococcus Tubo-Ovarian Abscess","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metronidazol","indication_name":"Peptostreptococcus Tubo-Ovarian Abscess","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metronidazol","indication_name":"Tubo-ovarian abscess","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pafolacianine","indication_name":"Imaging ovarian cancer and malignant lesions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytalux","generic_name":"PAFOLACIANINE","company_name":"On Target Labs","drug_phase":"marketed","molecular_target":"Folate receptor alpha","drug_class":"Optical Imaging Agent","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"olaparib-oral-product","indication_name":"Platinum-resistant/refractory high-grade serous ovarian cancer","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."},{"drug_id":"pf-07260437","indication_name":"Advanced or metastatic solid tumors (including ovarian, endometrial, and breast neoplasms)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07260437","generic_name":"pf-07260437","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Unknown","drug_class":"Unknown oncology compound","quality_score":null,"revenue":null,"mechanism":"Mechanism of action unknown; experimental oncology compound discontinued during Phase 1 development."},{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"High-grade serous ovarian cancer (idetrexed + olaparib)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."},{"drug_id":"felmetatug-vedotin","indication_name":"Ovarian Neoplasms","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Felmetatug Vedotin","generic_name":"felmetatug-vedotin","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Given into the vein (IV; intravenously)","quality_score":null,"revenue":null,"mechanism":"Given into the vein (IV; intravenously)"},{"drug_id":"endocrine-therapy-1","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endocrine Therapy 1","generic_name":"endocrine-therapy-1","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Endocrine Therapy 1","quality_score":null,"revenue":null,"mechanism":"Endocrine Therapy 1"},{"drug_id":"pegylated-liposomal-doxorubicin-pld","indication_name":"Ovarian Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pegylated Liposomal Doxorubicin (PLD)","generic_name":"pegylated-liposomal-doxorubicin-pld","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in","quality_score":null,"revenue":null,"mechanism":"RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in"},{"drug_id":"endocrine-therapy-2","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endocrine Therapy 2","generic_name":"endocrine-therapy-2","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Endocrine Therapy 2","quality_score":null,"revenue":null,"mechanism":"Endocrine Therapy 2"},{"drug_id":"pf-06873600","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06873600","generic_name":"pf-06873600","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-06873600 tablet for oral dosing","quality_score":null,"revenue":null,"mechanism":"PF-06873600 tablet for oral dosing"}],"offLabel":[],"totalMarketed":69,"totalPipeline":8},"trials":{"data":[{"nct_id":"NCT01267851","title":"Clinical Database and Biobank of Patients With Gynecologic Neoplasms","phase":"","overall_status":"UNKNOWN","enrollment_count":1600000,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05506800","title":"Guangzhou Women's Health Cohort Study (GWHCS)","phase":"","overall_status":"SUSPENDED","enrollment_count":1000000,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT04334239","title":"Effectiveness of Care in Certified Cancer Centres in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":670000,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT00058032","title":"CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women","phase":"NA","overall_status":"COMPLETED","enrollment_count":202638,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT06528236","title":"Research and Application of Ultrasonic Intelligent Diagnosis System for Ovarian Mass","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Zhejiang Provincial People's Hospital","has_results":false},{"nct_id":"NCT01696994","title":"Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":78216,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04473833","title":"Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":65000,"lead_sponsor_name":"John R van Nagell","has_results":false},{"nct_id":"NCT03518918","title":"Establishing the Diagnosis Standard and Analysis the Risk Factors of POI in Chinese Women","phase":"","overall_status":"UNKNOWN","enrollment_count":50000,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06129968","title":"Transforming Ovarian Cancer Diagnostic Pathways","phase":"","overall_status":"RECRUITING","enrollment_count":34000,"lead_sponsor_name":"Professor Sudha Sundar","has_results":false},{"nct_id":"NCT04494945","title":"Identifying and Caring for Individuals With Inherited Cancer Syndrome","phase":"NA","overall_status":"RECRUITING","enrollment_count":27500,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT05142033","title":"Avera Cancer Sequencing and Analytics Protocol (ASAP)","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Avera McKennan Hospital & University Health Center","has_results":false},{"nct_id":"NCT06995898","title":"The Vanguard Study: Testing a New Way to Screen for Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":24000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05204342","title":"Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France","phase":"","overall_status":"COMPLETED","enrollment_count":22500,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT04145388","title":"Family History Study on Cancer Risk","phase":"NA","overall_status":"UNKNOWN","enrollment_count":18623,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT04971304","title":"Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars","phase":"","overall_status":"COMPLETED","enrollment_count":16506,"lead_sponsor_name":"Catherine M. Lockhart","has_results":false},{"nct_id":"NCT05912972","title":"Development and Management of Registry in Patients With Gynecologic Cancer in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":13500,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT03275298","title":"Evolution of the Therapeutic Care in Ovarian Cancer From 2011","phase":"","overall_status":"SUSPENDED","enrollment_count":13331,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT06851429","title":"Ovarian Cancer Identification on CT Using Deep Learning","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12578,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT03598946","title":"Urinary Human Papilloma Virus Test in the General Population in Brittany","phase":"NA","overall_status":"UNKNOWN","enrollment_count":12500,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT00342446","title":"A Follow-up Study of Women Evaluated and Treated for Infertility","phase":"","overall_status":"COMPLETED","enrollment_count":12193,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00340600","title":"Continuation of Follow-up of DES-Exposed Cohorts","phase":"","overall_status":"COMPLETED","enrollment_count":10805,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04470921","title":"STOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the Netherlands","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT03517332","title":"Circulating Tumor DNA Exposure in Peripheral Blood","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Quantgene Inc.","has_results":false},{"nct_id":"NCT04214782","title":"Detection of Ovarian Cancer Using an Artificial Intelligence Enabled Transvaginal Ultrasound Imaging Algorithm","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03967457","title":"Comprehensive Study on the Quality of Life in Cervical Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT07039552","title":"Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT06515678","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9464,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT00539162","title":"Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women","phase":"NA","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03246841","title":"Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7274,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT00340210","title":"Extended Follow-up of Columbia, MO Serum Bank Participants","phase":"","overall_status":"COMPLETED","enrollment_count":6720,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00341458","title":"Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics","phase":"","overall_status":"COMPLETED","enrollment_count":6086,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06717295","title":"The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Javier Toledo","has_results":false},{"nct_id":"NCT06440018","title":"INSPIRE: a Multi-Cancer Early Detection Study","phase":"","overall_status":"RECRUITING","enrollment_count":5350,"lead_sponsor_name":"Singlera Genomics Inc.","has_results":false},{"nct_id":"NCT03662204","title":"Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":5133,"lead_sponsor_name":"Exact Sciences Corporation","has_results":false},{"nct_id":"NCT06223763","title":"SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","has_results":false},{"nct_id":"NCT05801263","title":"ctDNA Methylation for Epithelial Ovarian Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT03667417","title":"Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Institut Paoli-Calmettes","has_results":false},{"nct_id":"NCT03291262","title":"Survival Outcomes of Ovarian Malignancies in Chinese Population","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT06118307","title":"Shanghai Ovarian Cancer and Family Care Project","phase":"","overall_status":"RECRUITING","enrollment_count":3546,"lead_sponsor_name":"Shanghai First Maternity and Infant Hospital","has_results":false},{"nct_id":"NCT03382158","title":"International PPB/DICER1 Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3400,"lead_sponsor_name":"Children's Hospitals and Clinics of Minnesota","has_results":false},{"nct_id":"NCT06760507","title":"Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics","phase":"NA","overall_status":"RECRUITING","enrollment_count":3209,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT05051722","title":"Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":3110,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04294927","title":"TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention","phase":"NA","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"University Medical Center Nijmegen","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT05697601","title":"Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools","phase":"","overall_status":"UNKNOWN","enrollment_count":2905,"lead_sponsor_name":"Hasanuddin University","has_results":false},{"nct_id":"NCT05564377","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07009743","title":"O-RADS MRI System on Early Detection of Ovarian Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2549,"lead_sponsor_name":"Shanghai Gynecologic Oncology Group","has_results":false},{"nct_id":"NCT06324734","title":"Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting","phase":"","overall_status":"COMPLETED","enrollment_count":2506,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}